Oncotelic Therapeutics Reports $249 Million Net Income for Fiscal Year 2025

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) reported financial results for the fiscal year ended December 31, 2025, with net income of approximately $249.0 million compared to a net loss of $4.8 million in FY 2024. The substantial improvement was primarily driven by a non-cash gain of approximately $365.4 million from the increased valuation of its GMP Biotechnology joint venture, partially offset by a deferred tax provision of $111.6 million. This financial turnaround represents a significant milestone for the clinical-stage biopharmaceutical company focused on orphan oncology and advanced drug platforms.

The company's development pipeline includes OT-101 for various cancers and COVID-19 through its joint venture GMP Bio, with Dragon, Artemisinin for COVID-19, and AI technologies for clinical development and manufacturing. GMP Bio is developing five additional nanoparticle compounds in the joint venture, which has the potential for significant revenues and value. The company also acquired apomorphine for Parkinson's Disease, erectile dysfunction and female sexual dysfunction. Additional product candidates under evaluation include OXi4503 as a treatment for acute myeloid leukemia and myelodysplastic syndromes, and CA4P in combination with a checkpoint inhibitor for the treatment of advanced metastatic melanoma.

Oncotelic's corporate structure includes business activities conducted through Oncotelic and its wholly-owned subsidiaries: Oncotelic, Inc., PointR Data, Inc., Pet2DAO, Inc., and EdgePoint AI, Inc., for which there are non-controlling interests. The company is planning to address the animal health industry through Pet2DAO. The principal corporate office is located in Agoura Hills, California. The company maintains an internet presence at https://www.oncotelic.com where investors can access additional information about corporate developments and financial performance.

The financial results were distributed through BioMedWire, a specialized communications platform focusing on biotechnology, biomedical sciences and life sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN that provides access to wire solutions, article syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. Additional information about BioMedWire's services and disclaimers is available at https://www.BioMedWire.com. The platform's comprehensive distribution network ensures that breaking news and corporate announcements reach a wide audience of investors, journalists and industry professionals.

The company's transition from net loss to substantial net income positions it more favorably for continued development of its oncology pipeline and COVID-19 related treatments. The valuation gain from the GMP Biotechnology joint venture reflects growing confidence in the partnership's potential to develop nanoparticle compounds and other advanced therapies. This financial strengthening comes at a critical time as the company advances multiple clinical programs targeting various cancers and explores applications in animal health through its Pet2DAO initiative. The results demonstrate how strategic partnerships and joint ventures can create significant value for biopharmaceutical companies developing treatments for complex medical conditions.